| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | Bryostatin 1 | FIMM | pan-cancer | AAC | 0.049 | 0.8 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.01 | 0.8 |